ReviewAmerican journal of clinical dermatology2022
Clinical Course and Characteristics of Generalized Pustular Psoriasis.
Review in American journal of clinical dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Monotherapy with Biologics for Generalized Pustular Psoriasis: A Systematic Review of Comparative Interventional Studies with an Exploratory Network Meta-Analysis.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis.The Journal of dermatology · 2024Guideline
- Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis.Frontiers in immunology · 2024Pooled it
- Development and assessment of an artificial intelligence-based tool for scoring lesion severity in generalized pustular psoriasis clinical images.JID innovations : skin science from molecules to population health · 2026Article
- Generalized Pustular Psoriasis: A Cost-of-Illness and Health-Related Quality of Life Study in Italy.PharmacoEconomics - open · 2026Article
- Spesolimab for patients with generalized pustular psoriasis flares: Real-world experience in China.Chinese medical journal · 2026Article
- Clinical Practice Recommendations for Non-Dermatologists on the Diagnostic Suspicion of GPP.Journal of clinical medicine · 2026Review
- Enhanced Diagnosis of Generalized Pustular Psoriasis With the Legit.Health Device as a Diagnosis Support Tool: Multireader Multicase Study.JMIR dermatology · 2026Article
- Hospitalized generalized pustular psoriasis vs . acute generalized exanthematous pustulosis: A comprehensive analysis of clinical manifestations and treatment outcomes.Chinese medical journal · 2026Article
- Generalized pustular psoriasis exhibits highly variable flare intervals with no identifiable baseline predictors: A retrospective case series of 40 patients.JAAD international · 2026Article
- The Role of Genetic Testing in the Differential Diagnosis of Pustular Dermatoses: A Pediatric Case of Generalized Pustular Psoriasis Associated with the IL36RN Variant.Journal of clinical medicine · 2026Article
- Clinical differentiation between acute generalized exanthematous pustulosis and generalized pustular psoriasis: A multi-center study.Chinese medical journal · 2026Article
- An Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in Japan.Acta dermato-venereologica · 2026Article
- Juvenile Generalized Pustular Psoriasis: Management in Children-A Case Series.Clinical case reports · 2026Article
- Repeated Episodes of GPP Induced by Respiratory Infections Are Mediated by Loss-of-Function IFIH1.Immunity, inflammation and disease · 2026Article
- Complications and Laboratory Test Findings Among Patients With Generalized Pustular Psoriasis: A Retrospective Chart Review Study.Experimental dermatology · 2026Article
- Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland.Acta dermato-venereologica · 2026Article
- Real-World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP).The Journal of dermatology · 2026Article
- Sustained efficacy of spesolimab following flare-up dose in achieving long-term skin clearance in generalized pustular psoriasis: A case report and review of literature.JAAD case reports · 2026Article
- Apolipoprotein E drives microglia activation in the development of autoimmune uveitis through up-regulation of peptidyl prolyl isomerase F.Science advances · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterized by episodes of widespread sterile macroscopic pustules, with or without systemic inflammation and/or plaque psoriasis. Multiple GPP subtypes have been described, from acute GPP of von Zumbusch to milder, annular pustular psoriasis. Generalized pustular psoriasis mainly affects adults, with a female preponderance, but juvenile GPP also occurs. Flares are a hallmark of GPP and may occur de novo or be provoked by triggers, including withdrawal of systemic corticosteroids, infections, stress, pregnancy, and menstruation. Severity of flares varies widely between patients, and between flares in an individual patient. Significant flares are often accompanied by systemic symptoms, notably fever, general malaise, and extracutaneous manifestations such as arthritis, uveitis, and neutrophilic cholangitis. Common laboratory abnormalities include neutrophilia, elevated C-reactive protein levels, hypocalcemia, and abnormal liver function tests. The clinical course of GPP is highly variable; it can be a relapsing disease with recurrent flares and no pustulation between flares or a persistent disease with perpetual mild pustulation punctuated with flares of greater severity. Patients may have multiple flares per year or a flare every few years. Most flares last 2-5 weeks and approximately 50% require hospitalization. Life-threatening complications include sepsis and renal, hepatic, respiratory, and heart failure. Reported mortality rates are 2-16%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.